Lamictal (lamotrigine)
Lamictal (lamotrigine) belongs to the class of medications known as anti-epileptics. Lamictal is used alone or in combination with other medications for the management of seizures associated with epilepsy when more traditional medications have not been effective. Lamictal is also used along with other medications for the management of seizures associated with Lennox-Gastaut syndrome.
Lamotrigine
The recommended dose of lamotrigine varies according to needs and other anti-epileptic medications that the person is taking. Lamotrigine is started at a low dose, ranging from 25 mg every other day to 50 mg once a day. Over 4 weeks, the dose is gradually increased until a maintenance dose is reached. This dose ranges from 50 mg to 250 mg twice a day. Many things can affect the dose of medication that a person needs, such as body weight, other medical conditions, and other medications. If your doctor has recommended a dose different from the ones given here, do not change the way that you are taking the medication without consulting your doctor.
Buy Lamictal Online
When you buy Lamictal online at ABC Online Pharmacy your prescription will be filled quickly and without delay. Also, when purchasing Lamictal from ABC Online Pharmacy and your online order is over $450 you receive free shipping for your online prescription. There is also free shipping for seniors that buy Lamictal online.
Buy Lamictal Online (lamotrigine)
Canadian Lamictal
Lamictal ® is available as tablets and as chewable/dispersible tablets.
Tablets:
25 mg: Each white, scored, shield-shaped tablet, engraved with
"LAMICTAL" and "25", contains lamotrigine 25 mg. Nonmedicinal ingredients: cellulose,
lactose, magnesium stearate, povidone, and sodium starch glycolate.
100 mg: Each peach, scored, shield-shaped tablet, engraved with "LAMICTAL" and
"100", contains lamotrigine 100 mg. Nonmedicinal ingredients: cellulose, lactose, magnesium
stearate, povidone, sunset yellow FCF lake, and sodium starch glycolate.
150 mg: Each cream, scored, shield-shaped tablet, engraved with "LAMICTAL" and
"150", contains lamotrigine 150 mg. Nonmedicinal ingredients: cellulose, ferric oxide
(yellow), lactose, magnesium stearate, povidone, and sodium starch glycolate.
Chewable/dispersible tablets:
2 mg: Each white, round tablet, engraved "LTG", contains lamotrigine 2 mg.
5 mg: Each white, scored, biconvex tablet, engraved "LAMICTAL", contains
lamotrigine 5 mg.
Nonmedicinal ingredients: aluminum magnesium silicate, blackcurrant flavour, calcium
carbonate, hydroxypropyl cellulose, magnesium stearate, povidone, saccharin sodium, and sodium starch
glycolate.
Buy Canadian Lamictal (lamotrigine)
Lamictal Side Effects
Lamictal (lamotrigine) is usually very well tolerated. The most common side effects of Lamictal were:
- dizziness (more common for women)
- drowsiness
- headache
- nausea
- vomiting
- constipation
- diarrhea
- dryness of mouth
- indigestion
- loss of strength
- menstrual pain
- pain
- runny nose
- slurred speech
- trembling or shaking
- trouble sleeping
- unusual weight loss
Lamictal Precautions
Serious Rash: Pediatric Population: The incidence of serious rash associated with hospitalization and discontinuation of LAMICTAL in a prospectively followed cohort of pediatric patients with epilepsy receiving adjunctive therapy was approximately 0.8% (16 of 1,983). When 14 of these cases were reviewed by 3 expert dermatologists, there was considerable disagreement as to their proper classification. To illustrate, one dermatologist considered none of the cases to be Stevens-Johnson syndrome; another assigned 7 of the 14 to this diagnosis. There was 1 rash related death in this 1,983 patient cohort. Additionally, there have been rare cases of toxic epidermal necrolysis with and without permanent sequelae and/or death in US and foreign postmarketing experience. It bears emphasis, accordingly, that LAMICTAL is only approved for use in those patients below the age of 16 who have partial seizures or generalized seizures associated with the Lennox-Gastaut syndrome.
Adult Population: Serious rash associated with hospitalization and discontinuation of LAMICTAL occurred in 0.3% (11 of 3,348) of adult patients who received LAMICTAL in premarketing clinical trials of epilepsy. In he bipolar and other mood disorders clinical trials, the rate of serious rash was 0.08% (1 of 1,233) of adult patients who received LAMICTAL as initial monotherapy and 0.13% (2 of 1,538) of adult patients who received LAMICTAL as adjunctive therapy. No fatalities occurred among these individuals. However, in worldwide postmarketing experience, rare cases of rash-related death have been reported, but their numbers are too few to permit a precise estimate of the rate.
Lamictal Manufacturer
Lamictal is a registered trademark of GlaxoSmithKline
